How Ozempic and Weight Loss Drugs Are Reshaping This Country’s Economy

The Danish pharmaceutical company Novo Nordisk, known for its weight loss drugs Ozempic and Wegovy, is driving most of Denmark's recent economic growth and has become the second most valuable public company in Europe.

nytimes.com

Relevant topic timeline:

8/21/2023

How soaring demand for Ozempic and Wegovy is altering Denmark's economy

Sales of the weight-loss drug Wegovy, manufactured by Novo Nordisk, have led to lower interest rates in Denmark due to an influx of US dollars into the country's economy, which has pushed up the value of the Danish krone.

8/25/2023

Weight-Loss Drug Wegovy Will Launch In More Countries Despite Ongoing Struggles Over Stellar Demand, CEO Says

Novo Nordisk plans to launch its weight-loss drug Wegovy in more countries, despite shortages caused by high demand, according to CEO Lars Fruergaard Jorgensen.

9/1/2023

Weight loss drugmaker Novo Nordisk vies to become Europe's most valuable company, toppling LVMH

Novo Nordisk briefly surpassed LVMH to become Europe's most valuable company on the back of its weight loss drugs, but LVMH regained the top spot, although Novo Nordisk remains close behind with its highly anticipated drugs.

9/4/2023

Weight-loss drug Wegovy debuts in UK even as Novo Nordisk struggles with supplies

Novo Nordisk has launched its weight-loss injection, Wegovy, in the UK, following a controlled and limited launch, with a monthly supply priced between £199 and £299 for private patients through an online pharmacy chain.

9/6/2023

Morning Bid: Shedding pounds, buying dollars

Investors are eagerly anticipating the release of Novo Nordisk's weight-loss injection in British stores, while Manchester United shares plummeted after reports of the club being taken off the market; meanwhile, the dollar is strengthening, oil prices are rising, and concerns about weak demand and China's economy persist.

9/13/2023

Novo Nordisk Shares Drop After Stock Split, But Long Term Growth Prospects Still Strong Despite Valuation Concerns

Danish drugmaker Novo Nordisk's shares fell after a split aimed at increasing liquidity, but analysts remain optimistic about the company's leadership in the obesity drug market.

9/20/2023

Ypsomed Signs Long-Term Deal to Supply Autoinjectors for Novo Nordisk's Diabetes and Obesity Drugs

Ypsomed has announced a long-term supply deal with Novo Nordisk for autoinjectors, indicating the success of Novo Nordisk's weight-loss drug business and the potential for growth in the obesity market.

9/20/2023

Danish Economy Gets Boost from Novo Nordisk's Success Abroad

The Danish central bank has raised its economic growth forecast through 2025, attributing the increase to the success of Danish drugmakers such as Novo Nordisk, although it also noted that growth may be heavily skewed by activities outside of Denmark, particularly in the pharmaceutical industry.

9/20/2023

New Obesity Drugs Could Transform Health but Disrupt Major Industries

Anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health but could also disrupt industries such as food, fitness, and healthcare, affecting companies like Nestlé and McDonald's.